

GLOBAL FORUM

DRIVING IDEAS TO ACTION



LISTENING AND LEARNING FROM PATIENTS... P24

**Risk-Based Monitoring:
Hype, Paradigm Change or
New Frontier? ... p14**

**New Medical R&D Agency
in Japan... p38**

**EU QPPVs: The Responsibilities
and Risks are Real... p46**

**Review: IOM Report on Sharing
Clinical Trial Data... p48**



Beat Widler,
Quality Special
Section Editor, p7



Eric Racine,
Patient Centricity &
Empowerment, p24

AUGUST 2015
VOLUME 7 • ISSUE 4

DIA DEVELOP
INNOVATE
ADVANCE

Spotlight Your Expertise and Content to DIA's Members and Stakeholders

DIA Solution Provider Webinars

Share your solutions with professionals from industry, regulatory agencies, academic research centers, government, and patient organizations, through DIA Solution Provider Webinars:

- You share timely and relevant content that benefits your customers and prospects
- DIA promotes, hosts, and records your webinar
- You generate leads from webinar attendees' opt-in contact information

PARTICIPATING SOLUTION PROVIDERS:



DIA White Paper Library

Share your company's expertise in solving a particular problem or success in developing a specific new business practice, service, product, or technology through publishing a White Paper in DIA's online White Paper Library. DIA will preview and promote your White Paper in one of our member publications, deploy it in our White Paper Library, and provide you with lead retrieval data from your readers' opt-in contact information. White Papers subject to DIA review and approval.

DEVELOP.
INNOVATE. ADVANCE.

DIA volunteers, members, and staff provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials, throughout the year, all around the world.

DIA DEVELOP
INNOVATE
ADVANCE

Basel, Switzerland | Beijing, China | Horsham, PA, USA | Mumbai, India | Tokyo, Japan

Discover new opportunities at DIAGlobal.org

CONTACT:
Amy Barnett
Director of Client
Publishing Services
abarnett@influencem.com
267-419-8735

**Deliver content that
Informs your customers and
Advances your company
mission and message.**

Contents

- 4 Deputy Editor's Message
- 5 President's Message
- 6 *Global Forum* Editorial Board
- SPECIAL SECTION**
- 7 Why a Special Section about Quality?
- 8 What is Quality? DIA Quality Working Group
- 10 The Quality of Medical Information
- 14 Risk-Based Monitoring: Hype, Paradigm Change or New Frontier?
- 17 Quality Risk Management as a Survival Kit: From Idea to Implementation
- 21 A p-Value is only as Good as the Data: Challenges when Endpoints are Based on Subjective Assessments
- YOU NEED TO KNOW**
- 24 Listening and Learning from Patients
- 32 Australia Update: 32 Recommendations
- 33 Canada Update: Vanessa's Law, Labeling Regulations, and New ICH Role
- 35 China Update: Innovation and Convergence Will Propel Pharmaceutical R&D
- 36 EU Update: Off-Label Use of Medicines; Legislative Framework for Devices
- 37 India Update: Improving Regulatory Practices and Clinical Trials
- 38 Japan Update: Roles & Responsibilities of New Medical R&D Agency (AMED)
- 39 Middle East and Africa Update: Ebola Lessons Inform New Collaboration Paradigms
- 40 United States Update: Elevating the Patient Voice: Leveraging Patients' Expertise to Advance Drug Development
- CONNECT**
- 42 Have you Heard? DIA's Insightful Podcasts
- 44 Patient Access to Medicines: European HTA Cooperation Must Evolve - An Industry View
- 46 EU QPPVs: The Responsibilities and Risks are Real
- 48 Review: IOM Report on Sharing Clinical Trial Data
- IN MY VIEW**
- 51 Viewpoint: Clinical Data Sharing Requires Culture Change
- 52 Viewpoint: Clinical Data Sharing Matters to Patients
- 53 Pediatric Medical Product Development: *TIRS* September 2015
- CLOSING REFLECTIONS**
- 54 The Importance of Nomenclature — Pharmacoverging/Pharmacovergence

Publishing Information

Global Forum Staff

Judy Connors, Associate Director,
Editorial Services

Chris Slawicki, Senior Copywriter

Jenny Kimbel, Senior Editorial Assistant

Mission

DIA *Global Forum* provides a multidisciplinary, neutral forum for communicating information related to drug development and life cycle management on a global basis. The *Global Forum* disseminates content that is relevant to members' professional experiences, including international industry and regulatory updates and news of the association and its programs. The magazine is circulated electronically six times a year as a benefit of DIA membership.

Publishing and Subscription:

DIA Global Center
21 Dupont Circle NW, Suite 300
Washington DC 20036 USA
1.202.601.8900

Contact Information for Advertising:

Amy Barnett
Influence Media
Director, Client Publishing Services
DIA *Global Forum*
267.419.8735
The *Global Forum* (ISSN: 1944-1991) is a publication of the Drug Information Association.

Editorial Office:

Drug Information Association (DIA),
800 Enterprise Road, Suite 200,
Horsham, PA 19044-3595,
USA; phone - 215.442.6100;
fax: 215.442.6199.
Copyright © 2015, Drug Information Association.

The *Global Forum* (ISSN: 1944-1991) is produced six times a year, in February, April, June, August, October, and December. Back issues of most previously published issues are available online for members at www.diaglobal.org.

Design: Influence Media - 267.419.8734

DIA is a neutral organization that does not advocate for or against any issue. The views expressed by the individual authors or interviewees in the *Global Forum* are theirs and do not necessarily represent the views of the Drug Information Association.

Diversify your knowledge

DIA/FDA Oligonucleotide-Based Therapeutic Conference 2015

SEPTEMBER 9-11 | WASHINGTON, DC

DIA and FDA have convened industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development. This conference will continue to focus on dialogue between regulators and industry from CMC, nonclinical, clinical pharmacology, and clinical disciplines to address the developmental advances, safety, and challenges in the field of oligonucleotide-based therapeutics.

Key Considerations for Biosimilar R&D Workshop

SEPTEMBER 14-15 | SHANGHAI, CHINA

This comprehensive, high-level training program will provide a hands-on learning experience to those seeking to understand how a biosimilar product is developed, regulated, and registered for global commercialization. It will also provide information on unresolved issues that may further complicate the successful integration of biosimilars into common therapeutic practice.

Annual Joint DIA / EFGCP / EMA Better Medicines for Children Conference

OCTOBER 1-2 | LONDON, UK

Join key stakeholders in open discussion to overcome issues delaying children's access to innovative treatments. The participation by European and US regulators this conference enjoys each year, as well as the inclusion of the patient and health care professional perspective, provides a real 360-degree view of these concerns and developments, and a pathway to practical solutions for common issues. Learn, network, and share experience with your counterparts from other organizations in our neutral setting.

12th Annual Meeting DIA Japan 2015

A New Horizon of Innovation in Medicine Development

NOVEMBER 15-17 | TOKYO, JAPAN

Medicine development means continuously generating and analyzing data on the benefits and risks of drugs, medical devices, regenerative medicines and other health care products, from development through postmarketing, to identify the value of these products to the patients they were designed to benefit. Join our conversations and help transform the conventional paradigm from company-centered to patient-centered medicine development.

DIA DEVELOP
INNOVATE
ADVANCE

DIA Global Center
21 Dupont Circle NW, Suite 300
Washington, DC 20036

Basel, Switzerland | Beijing, China | Horsham, PA, USA | Mumbai, India | Tokyo, Japan



GET INVOLVED

Submit an abstract today to be considered for a future DIA conference.

Visit DIAGlobal.org/Abstracts

Discover new opportunities at DIAGlobal.org



QUALITY RISK MANAGEMENT AS A SURVIVAL KIT: From Idea to Implementation Guide for Risk-Based Monitoring Technologies



Randy Ramin-Wright
Director of Quality Risk Management
Clinerion Ltd.
Switzerland

Artem Andrianov, PhD
Managing Director
Cyntegritry Germany GmbH

Research and development returns in the pharmaceutical industry have halved in the past ten years¹, due to increasing trial complexity, regulatory scrutiny, and competition for patients and high quality sites. Efficient risk management has become more than advice today – it is part of the survival kit for a modern pharmaceutical company.


FDA's monitoring guideline (<http://www.fda.gov/downloads/Drugs/.../Guidances/UCM269919.pdf>) advises: "Monitoring should be tailored to your organization, the study protocol, and the product being tested"². This implies that the selection of monitoring methods should involve a thorough analysis of the study protocol, its execution, and the contributing parties, as well as the associated risks. Only after analysis of information

critical to the success and quality of the study is one prepared to define a Risk-based Monitoring (RbM) strategy that is commensurate with the study risk profile (See Figure 1).

Initially, GCP referred to RbM indirectly in §5.18.13, although the upcoming GCP E6R2 addendum (currently undergoing regulatory review)

puts stronger emphasis on this procedure. In accordance with the addendum, a sponsor should develop an approach to monitoring clinical trials which is systematic, prioritized, and **risk-based**. The addendum advises that **a combination of on-site and centralized monitoring activities is appropriate**. Additionally, it points out that **emerging advances in**

Figure 1: Comparison of the Traditional Monitoring approach and RbM.



technology may facilitate the remote monitoring of source data. This article will categorize available RbM technologies and how they can support clinical operations.

RbM Technology Can be Categorized by Different Factors:

BY IT INFRASTRUCTURE: CLOUD-BASED VS. ON-SITE SOLUTIONS

- 1. Cloud-Based:** Software as a Service (SaaS) approach makes RbM available via a web-portal. Organizations using these solutions do not need to take care of IT infrastructure.
 - a. Commodity Service:** These systems use the commodity cloud solutions and share

resources with other services. Sometimes concerns about data security keep some companies from using this infrastructure.

- b. Private Cloud:** Allocates a dedicated infrastructure for each customer so that computing resources and a higher level of stability and availability are assured. Data security is generally not a concern.
- 2. On-Site Solutions:** These solutions are located on servers of consumers of the RbM solution. An important advantage of this solution is nearness of data sources and, as a result, high speed of data access.

Major influencing factors regarding IT infrastructure

are location of service, skill specialization, and scalability. Location strongly influences the price. As a result, cloud solutions are cost efficient. Traditionally, on-site solutions have been implemented but cloud-based solutions are now more in demand as they also provide high levels of service but at significantly lower cost and more flexibility than traditional internal IT departments can generally provide.

BY DATA SOURCING

Data sourcing capabilities of RbM technology can differ by its data sources (e.g., EDC, CTMS) and by its data acquisition method (push vs. pull). Most of today's RbM solutions focus on EDC because EDC can deliver many risk-relevant parameters



(e.g., the number of enrolled patients, visit schedules, etc.). Some technology providers consolidate data sources in a data warehouse (data gets stored at one central location), while others apply an elastic network approach enabling configurable data source interfaces, where networks crawl different clinical recording systems and capture risk-relevant information.

BY RISK AREAS

1. Basic Risk Areas (Patient Safety, Site Performance, Data Quality, Fraud Detection)
2. Protocol-specific Risk Areas (Protocol Compliance)
3. Therapy-specific Risk Areas (ECG, Spirometry, Imaging, ePro)
4. Resource Availability
5. Vendor Oversight

Choice of technology should be driven by requirements and risk tolerance. For larger trials with extensive requirements, a solution with a broad set of features and predictive analytics is suitable. A cloud solution with an


elastic network is usually well suited for smaller trials.

BY FUNCTIONS

1. Risk Detection
2. Issue Management
3. Risk Mitigation Process
4. Predictive Analytics, Heuristics

Each solution differs in the provided feature set (see Figure 2). Risk detection, risk dashboards and reporting, issue management, and risk mitigation process, are among the most universal features. More advanced solutions provide predictive analytics and heuristics to identify residual risks.

Figure 2: Technology Landscape of Some RbM Providers



About the Authors

Artem Andrianov, PhD, serves as Managing Director for Cyntegrity Germany GmbH. He combines verified skills in management and leading international teams (China, Germany, India, the US, and elsewhere) with vast experience in developing software for the pharmaceutical industry, and has been responsible for numerous successful software projects in clinical data quality oversight. After graduating as a software engineer, Dr. Andrianov earned his PhD in Mathematical Methods and Software Complexes, and his Executive Master of Business Administration from Cass Business School (City University of London, UK).

Randy Ramin-Wright is Director of Quality Risk Management at Clinerion in Basel Switzerland and is responsible for the global business development of the clinical quality risk management products. He has more than twenty years experience in consulting, risk management, and implementing information management systems. He is a strategic ally and an active member of the Alliance for Clinical Research Excellence and Safety (ACRES), where he promotes the establishment of standardized clinical quality risk management services.

RBM IMPLEMENTATION

Experience shows that a staged approach is most effective with RbM.⁴ It provides opportunities to reflect and adjust the process. Successful RbM includes both appropriate governance and enabling e-tools. In other words: People, Process, and Technology are key to success. The stages in this approach:

1. **Proof of Concept:** Execute workshops to determine the appropriate RbM organization, process, and technology. Choose a suitable trial. Apply simple

e-tools, and establish and train an RbM Core Team on the RbM process and tools.

2. **Pilot:** In this stage, e-tools play a stronger role. The pilot team gains experience, so that an informed decision can be made on how to proceed.

3. **Lessons Learned:** During the pilot, the RbM Governance Team and the Study Management Team provide feedback regarding the process and technology. Upon pilot completion, the results are analyzed, consolidated, and presented to major

stakeholders.

4. **Adjust RbM:** Adapt the RbM approach and technology to be consistent with change requests.

5. **RbM Rollout:** RbM process and technology are fully integrated for the whole trial portfolio, progressively involving more studies.

Summing up, RbM is a journey of continuous improvement requiring mechanisms for process change and a new way of working and thinking within the organization. ○



Key take-away Messages:

- Tools are essential for implementing RbM successfully as they enable recurring evaluation of risks and sites profiles.
- Today's technology solutions vary significantly and their suitability depends strongly on your situation and risk tolerance.
- When implementing RbM, apply a staged approach.
- Plan on bringing external expertise, if needed; it will reduce risks introduced by RbM.

References

1: KPMG, "Future Pharma," Aug-2011. [Online]. Available: http://www.biodeutschland.org/tl_files/content/dokumente/biothek/Future%20Pharma.pdf. [Accessed: 03-Jul-2015].

2: FDA, "Guidance for Industry Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring," Aug-2013. [Online]. Available: <http://www.fda.gov/downloads/Drugs/.../Guidances/UCM269919.pdf>. [Accessed: 15-Aug-2014].

3: International Conference on Harmonisation (ICH), "Guideline for Good Clinical Practice." Jul-2002.

4: B. Widler, J. Schenk, P. Schiemann, A. Andrianov, M. Proupin-Pérez, and M. Alsumidaie, "RbM Guidance Document: Ten Burning Questions about Risk-Based Study Management," *Applied Clinical Trials*, vol. Risk Based Monitoring, May-2015.

5: B. Wilson, T. Provencher, J. Gough, S. Clark, R. Abdrachitov, K. de Roeck, S. J. Constantine, D. Knepper, and A. Lawton, "Defining a Central Monitoring Capability: Sharing the Experience of TransCelerate BioPharma's Approach, Part 1," *Therapeutic Innovation & Regulatory Science*, Vol. 48, Iss. 5, September 2014.

A p-Value is only as Good as the Data: Challenges when Endpoints are Based on Subjective Assessments

Mimmo Garibbo
Ethical GmbH,
Switzerland

Beat Widler, PhD
Widler & Schiemann
Ltd., Switzerland



When endpoints are based on subjective assessments rather than objective data, a process of centralized endpoint adjudication can improve the quality of a clinical trial.

INTRODUCTION

WHAT IS ENDPOINT ADJUDICATION?

In many therapeutic areas, the baseline and end of trial assessments are based on the assessment of an image (e.g., tumor size), a tracing (e.g., ECG), or on the patients' or doctors' subjective assessment on a scale (e.g., visual analogue scales to rate pain, Hamilton scale to rate severity of depression). To reduce the observers' bias in a multi-center trial it is critical that assessments of such endpoints be "validated" (i.e., transparent and binding rules on how to perform the assessment are defined and agreed upon). Bias can also be introduced when treatment is unblinded or becomes unblinded; the rater's expectations may

result in inaccurate readings. Training of raters is an essential component of the quality strategy when subjective assessments are involved. However, an adequate quality control strategy needs to be implemented as well. An effective quality management approach is represented by a central baseline assessment and at the follow-up assessments of efficacy or safety parameters by a panel of independent experts following a blinded standardized procedure. A centralized assessment by a limited number of trained raters increases the accuracy of the readings, results in more independence of the raters, and thus prevents "observers' bias" and yields more homogeneous assessments or ratings.

WHEN ENDPOINT ADJUDICATION IS USED, IN WHICH THERAPEUTIC AREAS AND HOW FREQUENTLY

Analysis¹ of new marketing authorization applications / NDAs in 2013 and first quarter 2014 to FDA and EMA, respectively, showed that in 69% of the NMEs approved in the US and 41% of EMA approvals, some sort of adjudication method was used in phase 3 development programs. Medicinal products developed for oncology and endocrinology indications typically used an independent review committee (IRC) in line with recommendations made in relevant regulatory guidance, whereas in trials in nervous system or with

result in inaccurate readings. Training of raters is an essential component of the quality strategy when subjective assessments are involved. However, an adequate quality control strategy needs to be implemented as well. An effective quality management approach is represented by a central baseline assessment and at the follow-up assessments of efficacy or safety parameters by a panel of independent experts following a blinded standardized procedure. A centralized assessment by a limited number of trained

Figure 1 - 2013 & 1st Quarter 2014 FDA NME approvals

